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 Abstract:  
Abstract 
Aim To identify factors associated with prescribing potentially inappropriate medications (PIMs) in 
older adults (≥ 65 years) with complex care needs, who have undertaken a comprehensive geriatric 
risk assessment. Methods: A nationwide cross-sectional (retrospective, observational) study was 
performed. The national interRAI Home Care assessments conducted in New Zealand in 2015 for 
older adults were linked to the national pharmaceutical prescribing data (PHARMS). The 2015 
Beers criteria were applied to the cross-matched data to identify the prevalence of PIMs. The 
factors influencing PIMs were analysed using a multinomial logistic regression model. Results: 
16,568 older adults were included in this study. Individuals diagnosed with cancer, dementia, 
insomnia, depression, anxiety, and who were hospitalized in the last 90 days, were more likely to 
be prescribed PIMs than those who were not diagnosed with the above disorders, and who were 
not hospitalized in the last 90 days. Individuals over 75 years of age, the Māori ethnic group among 
other ethnicities, individuals who were diagnosed with certain clinical conditions (diabetes, chronic 
obstructive pulmonary disease, stroke, or congestive cardiac failure), individuals requiring 
assistance with activities of daily living and better self-reported health, were associated with a 
lesser likelihood of being prescribed PIMs. Conclusion: The study emphasizes the identification of 
factors associated with the prescription of PIMs during the first completed comprehensive 
geriatric assessment. Targeted strategies to reduce modifiable factors associated with the 
prescription of PIMs in subsequent assessments has the potential to improve medication 
management in older adults. 
Key words: Geriatric Assessment, Home Care Services, Logistic models, New Zealand, Potentially 
Inappropriate Medication List, Risk Assessment. 
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 1. Introduction: 
Optimal use of numerous medications in the geriatric population is often debated and difficult 
to achieve, and there is a high prevalence of inappropriate medication use.1 Several 
characteristics of ageing (alterations in pharmacokinetics and pharmacodynamics, frailty, 
geriatric syndromes, increased number of medications, multiple concomitant illnesses) influence 
prescribing for older adults.2  
Identifying potentially inappropriate medications (PIMs) by the application of criterion-based 
explicit screening tools is the most common method3, of which the Beers Criteria are commonly 
used to assess inappropriate prescribing of medications in older adults.4 
Pharmacopeidemiological studies conducted in New Zealand (NZ) have reported the prevalence 
of PIMs in community-dwelling older people and for individuals living in residential aged-care 
facilities as 42.7% and 40.9% respectively.5, 6 Several studies have focussed on the predictors of 
PIMs in older adults in various settings; however, the evidence for factors influencing the 
prescription of PIMs in home based older adults with complex care needs is limited.7 Consequent 
to the higher prevalence of PIMs in older adults in NZ, it is important to identify factors 
associated with the prescription of PIMs, and to better target interventions to reduce their 
occurrence.8  
Comprehensive geriatric risk assessment in home care using the interRAI-HC (International 
Resident Assessment Instrument-Home care) tool has been mandated in NZ since 2015 for all 
community-care older adults, and they contain information on multiple domains.9 
The primary aim of the study is to identify factors associated with the prescription of PIMs in 
older adults who have undertaken a comprehensive geriatric risk assessment. 
 
2. Methods:  
We obtained the approval of the institutional review board: Ethical approval number 
15/CEN/45/AM02.  
2.1 Data source: The retrospectively conducted cross-sectional study utilized the comprehensive 
geriatric assessment, interRAI-HC (International Resident Assessment Instrument-Home Care)-
PHARMS (Pharmaceutical Claims Data Mart) matched dataset for extracting anonymous data of 
all older individuals aged 65 years and above who were dispensed at least one prescription 
medication between January to October 2015. The data source is described previously 
elsewhere.10 For this study, where an individual had undertaken multiple geriatric risk 
assessments in 2015, we only utilized the first comprehensive geriatric risk assessment. 
The PHARMS extract files for 2015 furnished information pertaining to the prescription claims 
prepared by community pharmacists and funded by PHARMAC (Pharmaceutical management 
agency).  
 
2.2 Study population: 16,568 community-dwelling individuals, aged 65 years and older, living 
in NZ, who have undertaken the first comprehensive geriatric risk assessment, and have received 
one or more prescription medications in 2015 were included. 
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 2.3 PIMs exposure: The individuals who were prescribed at least one inappropriate medication 
in 2015, according to the 2015 Beers criteria 11 were classified as those prescribed PIMs.  
 
2.4 Covariates: A scoping literature review was performed to determine the most common 
factors influencing the prescribing of PIMs in older adults. The individuals were categorised in 
four age groups of 65-74 years, 75-84 years, 85-94 years, and over 95 years. Data analysis was 
performed for all ethnicities with specific emphasis for NZ Europeans and Māori, as they are in 
majority in NZ.5 
Based on the scoping literature, a number of explanatory variables were tested for their 
influence on prescribing patterns of PIMs, and these included: 
A. Sociodemographic: Age, sex, ethnicity, marital status, alcohol intake, smoking, living 
arrangements, number of medications. 
B. Clinical: Activities of daily living, self-reported health, hospitalization, dementia, insomnia, 
depression, anxiety, hemiplegia, Parkinson’s disease, stroke, coronary heart disease (CHD), 
congestive cardiac failure (CCF), diabetes, chronic obstructive pulmonary disease (COPD), bowel 
incontinence, urinary incontinence, urinary tract infection, falls, fracture, cancer. Although the 
Beers criteria 2015 excludes patients requiring palliative care, we have included cancer as a risk 
factor associated with PIMs. 
 
2.5 Statistical analysis:  
STrengthing the Reporting of Observational studies in Epidemiology (STROBE) guidelines 
(www.strobe-statement.org) was used to report all analyses conducted for this study (Appendix 
I). A multinomial logistic regression model was used to measure the relationship between PIMs 
use and all explanatory variables. 1-2 PIMs and more than equal to three (>3) PIMs were the 
outcome variables. Individuals not prescribed PIMs (nil PIMs) formed the reference group. 
Individuals with a diagnosis of any of the clinical ailments mentioned above were flagged as a 
binary variable; those with the diseased condition were coded as 1, the coding for no ailments 
was 0. The explanatory variables were tested for multi-collinearity. Model assumptions were 
tested using the Hosmer-Lemeshow goodness-of-fit test. All descriptive statistics were 
conducted using IBM SPSS version 24. Multinomial regression analysis was performed using 
StataCorp® Release 14.2. 
 
3. Results:  
InterRAI-HC information and prescription use data for 16,568 individuals aged 65 years and 
older were extracted; of these, females constituted 60.1% (9,964). The mean age of the 
individuals was 82.35 (±7.6) years. Table 1 illustrates the sociodemographic variables of the 
population studied, and Table 2 displays the associations of PIMs with the investigated variables 
according to the corresponding 95% confidence interval (CI) (p<0.05). We have independently 
considered the associations of 1-2 PIMs and > 3 PIMs for each individual.   
3.1 Sociodemographic factors: 
 Males were prescribed a slightly higher number of PIMs than the females (~43.1% for 1-2 PIMs 
and ~48% for three or more PIMs); individuals over 75 years of age were less likely to be 
prescribed PIMs (35.6% for 1-2 PIMs and 57.7% for >3 PIMs), compared to individuals aged 65-75 
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 years, and the Māori ethnic group were less likely to be prescribed PIMs (47.5% for 1-2 PIMs, 
41.3% for >3 PIMs) compared to the NZ Europeans (43.1% for 1-2 PIMs and 48.9% for >3 PIMs). 
Also, individuals who were prescribed a greater number of medications were more likely to be 
prescribed PIMs [aOR (Adjusted Odds Ratio) =1.12, CI=1.11, 1.13 for 1-2 PIMs, and aOR=1.22, 
CI=1.21, 1.23 for >3 PIMs), compared to individuals prescribed a single medication. 
3.2 Clinical factors associated with 1-2 PIMs: 
With respect to the activities of daily living, the individuals who were being supervised 
(aOR=0.82, CI=0.68, 0.98), who required extensive care (help throughout task, but performed 
50% or more of the task on their own) (aOR=0.74, CI=0.56, 0.97), and who required maximal care 
(help throughout task, but performed less than 50% of task on their own) (aOR=0.67, CI=0.47, 
0.95), were less likely to be prescribed 1-2 PIMs, compared to individuals who were independent 
in their self-performance and capacity. Individuals who reported good self-health (aOR=0.74, 
CI=0.56, 0.98) were less likely to be prescribed 1-2 PIMs compared to individuals who reported 
poor self-health. Individuals diagnosed with diabetes (aOR=0.75, CI=0.63, 0.89) were less likely to 
be prescribed 1-2 PIMs compared to individuals not diagnosed with diabetes. Individuals 
diagnosed with insomnia (aOR=1.44, CI=1.23, 1.69) were more likely to be prescribed 1-2 PIMs, 
compared to the individuals not diagnosed with insomnia. Individuals who were diagnosed with 
stroke (aOR=0.69, CI=0.58, 0.52) or COPD (aOR=0.79, CI=0.65, 0.96) had a lesser likelihood of 
being prescribed 1-2 PIMs, compared to the individuals who were not diagnosed with either of 
the diseases. 
3.3 Clinical factors associated with >3 PIMs: 
Individuals who reported excellent (aOR= 0.62, CI=0.41, 0.93) and good self-health (aOR=0.63, 
CI=0.47, 0.85) were less likely to be prescribed >3 PIMs compared to individuals who reported poor 
self-health. Individuals who were hospitalized in the last 90 days (aOR= 1.19, CI=0.47, 0.85) were 
more likely to be prescribed >3 PIMs, compared to individuals who had not undergone 
hospitalization in the last 90 days. Individuals diagnosed with cancer (aOR=1.35, CI=1.11, 1.66) were 
more likely to be prescribed >3 PIMs, compared to individuals with no diagnosis of cancer. 
Individuals with the diagnosis of diabetes (aOR=0.65, CI=0.54, 0.77) had a lesser likelihood of being 
prescribed >3 PIMs, compared to individuals not diagnosed with diabetes. Individuals diagnosed 
with dementia (aOR=1.26, CI=1.05, 1.51) were more likely to be prescribed >3 PIMs, compared to 
individuals not diagnosed with dementia. Individuals with the diagnosis of insomnia (aOR=1.80, 
CI=1.53, 2.11) had a greater likelihood of being prescribed >3 PIMs, compared to individuals not 
diagnosed with insomnia. Individuals diagnosed with anxiety (aOR=1.77, CI=1.32, 2.36) and 
depression (aOR=1.68, CI=1.28, 2.19) had a higher odds of being prescribed >3 PIMs compared to 
individuals who were not diagnosed with either of the conditions. Individuals diagnosed with CCF 
(aOR=0.76, CI= 0.62, 0.93) were less likely to be prescribed >3 PIMs, compared to individuals not 
diagnosed with CCF. Similarly, individuals diagnosed with stroke (aOR=0.56, CI=0.47, 0.67) or COPD 
(aOR=0.51, CI=0.41, 0.63) were less likely to be prescribed >3 PIMs compared to individuals not 
diagnosed with either of the 2 ailments. 
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 4. Discussion: 
The present study identified the factors associated with prescribing PIMs in the older adults of 
NZ who have undertaken a comprehensive geriatric risk assessment.10 Several important 
sociodemographic and clinical factors predicted the use of PIMs in this population. 
4.1 Sociodemographic factors of PIMs:  
The current study demonstrates the significant independent relationship between prescription 
of PIMs and the male gender, the youngest group of older adults ( age group 65-75 years), NZ 
Eurpoeans, and the prescription of a greater number of medications to each patient, after 
adjusting for several important confounders. The higher likelihood of prescribing PIMs in the age 
group of 65-74 years is similar to the findings of a study conducted by Willcox et al in 6,171 
community-dwelling older adults. In their study, increasing age was associated with a lesser 
likelihood of being prescribed PIMs.12 The findings may reflect better attention to patient safety 
concerns and avoidance of PIMs in increasingly older individuals.8 Our study found an increased 
prescription of PIMs in NZ Europeans compared to the Māori population.10 This could be 
attributed to the fact that the Māori group receives lesser prescriptions compared to the non-
Māori population.13 It has conclusively been shown that prescription of a higher number of 
medications increases the risk of PIMs.14 Patients who are prescribed multiple medications are 
more likely to have multiple comorbid conditions, treatment under multiple physicians, recent 
hospitalizations, which explain all reasons why PIMs may be prescribed.14 
4.2 Clinical factors of PIMS: 
Our study reported a significant relationship between poor self-health and the prescription of 
PIMs, akin to the observation made by Howard et al 15 in a clinical trial of 889 community 
dwelling elderly patients recruited from randomly selected family practices in Ontario. A study 
conducted by Hanlon et al in frail veteran older adults showed that poor self-rated health was a 
significant determinant of PIMs use.16  
Individuals hospitalized during the assessment or in the past 90 days were prescribed a higher 
number of PIMs. The results are analogous to the findings of a longitudinal cohort Swedish 
National Study on Aging and Care (SNAC).17 In the SNAC study, individuals over 60 years of age in 
certain age groups were recruited from the Swedish national population, and examined. The 
findings are also consistent with a recent study conducted in community-dwelling elderly 
population in NZ, in which the number of prescription medications increased considerably after 
hospital admission in the past 12 months.18 Hospitalization is a setting in which older adults are 
likely to be exposed to PIMs.19 The impact of hospitalisation on PIMs use has been investigated 
in a study conducted by Hale LD et al 20, and was found to be significantly higher after hospital 
admissions.  
Our analysis revealed that individuals diagnosed with insomnia, dementia, anxiety, depression, 
and cancer had an increased likelihood for prescription of PIMs. The observations of a cross-
sectional study based on annual outpatient claims data in elderly outpatients in Taiwan correlate 
the high prevalence of prescription of PIMs in patients diagnosed with insomnia.21 With ageing, a 
greater number of older adults are diagnosed with insomnia; and hence psychoactive 
medications are more frequently prescribed to older adults by physicians, thereby culminating to 
the prescription of PIMs.22 Extavour et al have demonstrated the association of a clinical 
diagnosis of dementia to prescribing of inappropriate psychotropic medications, while assessing 
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 medications for older community-dwelling adults in the USA.23 A community-based cross-
sectional study in Lebanon utilizing the 2012 Beers criteria supports the finding of a higher 
association of PIMs with dementia, in patients aged 65 years and over.24 Findings from the SNAC 
study also point towards a high prevalence of PIMs in the population diagnosed with dementia.17 
Suboptimal prescribing can lead to considerable morbidity, especially in older patients with 
dementia, who may be more vulnerable to adverse events.25  
Our study reported that individuals with a diagnosis of cancer were prescribed a greater 
number of PIMs than individuals not diagnosed with cancer. Similar findings are echoed in a 
retrospective cross-sectional study conducted in the USA, analysing PIMs in veterans residing in 
community living centres whereby a strong relationship between cancer and PIMs were 
reported.26 PIMs warrant substantial interest and concern for prescribing in cancer patients 
because of the perils associated, which include increased risk of falls and/or fractures, cognitive 
impairment, and delirium, all of which can lead to compromised cancer management plans (e.g. 
treatment delays and/or premature treatment discontinuation).27  
In our study we observed that the prevalence of PIMs was lower in individuals who were being 
supervised, who required maximal or extensive care, than in individuals with functional 
independence, contrary to the observations reported by a study conducted by Miller et al in 
community-dwelling older adults in USA utilizing the 2012 Beers criteria, who examined the 
determinants of prescription of PIMs by estimating the multivariate models of the relationship 
between PIMs use and a broad range of socioeconomic and health characteristics in a nationally 
representative sample of USA civilian, noninstitutionalized population of older adults.8  The 
findings of our study portray that individuals with a functional dependence had better patient 
safety concerns and avoidance of PIMs with respect to ADL. We investigated that individuals 
diagnosed with COPD, stroke, or CCF, had a lower prevalence of PIMs prescribed, compared to 
those not diagnosed with these diseases. CCF and COPD were associated with PIM s use in other 
studies conducted globally in hospitalized elderly and elderly surgical patients.28  
The factors influencing PIMs vary among different studies because of different research 
designs, several versions of the Beers criteria, and different criteria applied, dissimilar prescribing 
guidelines in different countries, and differing study population characteristics and settings 
(outpatient, continuing care, residential).  
4.3 Strength of the study: 
A nationwide database was used to identify the associations of PIMs in the geriatric population 
of NZ. The selection bias is overlooked due to the wide prescription coverage in this population. 
A standardized interRAI HC assessment conducted by trained healthcare professionals has the 
advantage of providing valid clinical, social and functional information. Several determinants 
included in the multivariate regression model such as self-reported health, living status, and 
cognition, are rarely available in studies that used the administrative claims data; hence, this 
study provides a unique perspective to the factors associated with PIMs use in the geriatric 
population. The long-term implications of this study have the potential to impact prescribing in 
the older population of NZ, and help in developing an appropriate tool for prescribing.  
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 4.4 Limitations: 
Some of the medications listed in the Beers criteria were not available in NZ or not funded by 
PHARMAC (Appendix II). The findings of the study may not be generalised to other countries 
because of different health-care systems, prescribing guidelines, and treatment expenditures, as 
they inﬂuence prescribing patterns. The population studied is a high-risk population requiring 
complex care needs, unlike other study populations. Medications such as over-the-counter 
medications not captured by the prescription claims dataset may have underestimated the 
exposure to PIMs in this study population.  
We couldn’t assess the dispensing of antipsychotics for behavioural problems of dementia or 
for short-term use as an anti-emetic, and thus we excluded them from the analysis. The Beers 
criteria 2015 does not consider the prescription of antipsychotics for schizophrenia and bipolar 
disorders as PIMs, and hence, antipsychotic prescriptions for these conditions were excluded 
from the analyses. The interRAI assessment does not capture diagnoses of atrial fibrillation, 
hypogonadism, recently decompensated heart failure, removal of the pituitary gland, delirium, 
Barrett’s esophagitis, gastroparesis, pathological hypersecretory condition, peptic ulcers, lower 
urinary tract symptoms, chronic kidney disease, benign prostatic hypertrophy, and hence, these 
diagnoses were excluded from the analyses. Hypertension is not diagnosed by the interRAI 
assessment; hence, the prescription for clonidine and peripheral alpha blockers as anti-
hypertensive agents could not be confirmed. The information to identify specific conditions for 
prescriptions with oestrogens was unavailable. 
 
5. Conclusion:  
The present study found several sociodemographic and clinically relevant factors associated with 
PIMs use. Together with the results of our study, the published evidence demonstrates that the 
prescription of inappropriate medications to older people is influenced by a variety of factors, and 
although we highlight a greater number of medications and recent hospitalizations as a factor 
directly related to the prescription of PIMs, other important factors include functional status, 
reported self-health, the diagnosis of chronic obstructive pulmonary disease and congestive 
cardiac failiure. Identification of the modifiable determinants of PIMs, such as, number of 
medications isemphasised during the first completed comprehensive geriatric assessment. 
Targeted strategies to reduce modifiable determinants of PIMs in subsequent assessments has the 
potential to improve medication management in older adults.  
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 Table 1: Characteristics of the study population (N=16,568) 
 Total 
 N (%) 
Age (years) 
65-74 3,048 (18.4) 
75-84 6,776 (40.9) 
85-94 6,192 (37.4) 
95+ 552 (3.3) 
Sex † 
Female 9,964 (60.1) 
Male 6,603 (39.9) 
Ethnicity 
European 14,639 (88.4) 
Māori 957 (5.8) 
Other 972 (5.9) 
Marital status 
Married 6,607 (39.9) 
Other 9,961 (60.1) 
Alcohol   
No 13,225 (79.8) 
Yes 3,343 (20.2) 
Smoking   
No 15,653 (94.5) 
Yes 915 (5.5) 
Living arrangements 
Alone 8,019 (48.4) 
Spouse only 5,447 (32.9) 
Other 1,292 (7.8) 
With child ‡ 1,810 (10.9) 
Activities of daily living § 
Independent 9,985 (60.3) 
Supervision 2,143 (12.9) 
Limited 1,782 (10.8) 
Extensive 1,046 (6.3) 
Maximal 730 (4.4) 
Dependent+ 880 (5.3) 
Self-reported health 
Poor 1925 (11.6) 
Excellent 522 (3.2) 
Good 6,806 (41.1) 
Fair 5,695 (34.4) 
Couldn’t  respond 1,620 (9.8) 
Hospitalisation 
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 No hospitalisation|| 8,602 (51.9) 
Other 7,966 (48.1) 
Cancer 
No 13,706 (82.7) 
Yes 2,862 (17.3) 
Dementia 
No 14,378 (86.8) 
Yes 2,190 (13.2) 
Insomnia 
No 11,795 (71.2) 
Yes 4,773 (28.8) 
Depression 
No 14,653 (88.4) 
Yes 1,915 (11.6) 
Bipolar  
No                                        16,404 (99.0) 
Yes 164 (1.0) 
Anxiety 
No 15,046 (90.8) 
Yes 1,522 (9.2) 
Schizophrenia 
No 16,441 (99.2) 
Yes 127 (0.8) 
Hemiplegia 
No 16,148 (97.5) 
Yes 420 (2.5) 
Parkinson’s Disease 
  No 16,014 (96.7) 
  Yes                               554 (3.3) 
Stroke 
   No 13,895 (83.9) 
  Yes                                             2,673 (16.1) 
Coronary heart disease 
  No 11,670 (70.4) 
 Yes                   4,898        (29.6) 
Congestive-cardiac failure                  
  No                                                      13,895       (83.9) 
 Yes                                                 2,673             (16.1) 
Diabetes 
No 13,154 (79.4) 
Yes 3,414 (20.6) 
COPD* 
   No 13,929 (84.1) 
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   Yes                                                               2,639            (15.9) 
Bowel Incontinence 
   No 13,666 (82.5) 
   Yes                                     2,902 (17.5) 
Urinary Incontinence ** 
   No 9,767 (59.0) 
   Yes 6,785 (41.0) 
Urinary tract infection 
    No 15,492 (93.5) 
   Yes                                          1,076 (6.5) 
Falls 
  No 9,693 (58.5) 
  Yes 6,875 (41.5) 
Fracture †† 
   No 15,830 (95.5) 
   Yes                                          734 (4,4) 
†= 1 missing, ‡= not spouse / partner, §=2 missing, ||,= in last 90 days, *= Chronic Obstructive 
Pulmonary Disease, **=16 missing, †† =4 missing,  
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 Table 2: Determinants of PIMs and confounding variables with odds ratio (OR) and 95% confidence 
intervals (CI), after multinomial regression (N=16,568) 
 1-2 PIMs > 3 PIMs 
 aOR 95% CI p-value aOR 95% CI p-value 
Age (years) 
65-74 1* 1*  1* 1*  
75-84 0.94 (0.78, 1.14) 0.557 0.69 (0.57, 0.85) <0.001 
85-94 0.76 (0.63, 0.94) 0.009 0.46 (0.37, 0.57) <0.001 
95+ 0.66 (0.48, 0.93) 0.016 0.31 (0.21, 0.44) <0.001 
Sex † 
Female 1* 1*  1* 1*  
Male 1.3 (1.13, 1.49) <0.001 1.36 (1.18, 1.57) <0.001 
Ethnicity 
European 1* 1*  1* 1*  
Māori 0.76 (0.59, 0.98) 0.035 0.50 (0.38, 0.65) <0.001 
Other 0.81 (0.64, 1.05) 0.118 0.63 (0.48, 0.82) 0.001 
Marital status 
Married 1* 1*  1a 1*  
Other 1.04 (0.82, 1.34) 0.716 0.98 (0.76, 1.27) 0.890 
Alcohol 
No 1* 1*  1* 1*  
Yes 1.0 (0.86, 1.16) 0.991 1.04 (0.89, 1.23) 0.597 
Smoking 
No 1* 1*  1* 1*  
Yes 0.95 (0.73, 1.22) 0.686 0.82 (0.62, 1.09) 0.188 
Living arrangements 
Alone 1* 1*  1* 1*  
Spouse only 1.16 (0.88, 1.52) 0.268 1.15 (0.87, 1.53) 0.307 
Other 0.75 (0.59, 0.95) 0.022 0.89 (0.69, 1.16) 0.415 
With child ‡ 0.88 (0.73, 1.07) 0.234 0.83 (0.67, 1.03) 0.099 
Activities of daily living § 
Independent 1* 1*  1* 1*  
Supervision 0.82 (0.68, 0.98) 0.028 0.84 (0.68, 1.00) 0.072 
Limited 0.93 (0.74, 1.17) 0.525 0.88 (0.69, 1.12) 0.311 
Extensive 0.74 (0.56, 0.97) 0.028 0.75 (0.57, 1.01) 0.055 
Maximal 0.67 (0.47, 0.95) 0.023 0.75 (0.52, 1.08) 0.119 
Dependent+ 0.84 0.58, 1.20) 0.345 0.81 (0.55, 1.17) 0.262 
Self Reported health 
Poor 1* 1*  1* 1*  
Excellent 0.71 (0.48, 1.03) 0.073 0.62 (0.41, 0.93) 0.023 
Good 0.74 (0.56, 0.98) 0.042 0.63 (0.47, 0.85) 0.003 
Fair 0.89 (0.66, 1.19) 0.454 0.78 (0.58, 1.05) 0.105 
Couldn’t  respond 0.85 (0.61, 1.19) 0.363 0.88 (0.62, 1.25) 0.481 
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 Hospitalisation 
No hospitalisation|| 1* 1*  1* 1*  
Other 1.1 (0.96, 1.28) 0.155 1.19 (1.02, 1.38) 0.021 
No of medications 1.12 (1.11, 1.13) <0.001 1.22 (1.21, 1.23) <0.001 
       
Cancer 
No 1* 1*  1* 1*  
Yes 1.16 (0.95, 1.42) 0.156 1.35 (1.11, 1.66) 0.004 
Dementia 
No 1* 1*  1* 1*  
Yes 1.11 (0.94, 1.31) 0.219 1.26 (1.05, 1.51) 0.011 
Insomnia 
No 1* 1*  1* 1*  
Yes 1.44 (1.23, 1.69) <0.001 1.80 (1.53, 2.11) <0.001 
Depression 
No 1* 1*  1* 1*  
Yes 1.24 (0.96, 1.61) 0.098 1.68 (1.28, 2.19) <0.001 
Anxiety 
No 1* 1*  1* 1*  
Yes 1.12 (0.84, 1.48) 0.431 1.77 (1.32, 2.36) <0.001 
Hemiplegia 
No 1* 1*  1* 1*  
Yes 1.22 (0.79, 1.88) 0.368 0.80 (0.51, 1.27) 0.351 
Parkinson’s Disease 
  No 1* 1*  1* 1*  
  Yes                               0.93 (0.63, 1.37) 0.726 0.86 (0.58, 1.3) 0.487 
Stroke 
   No 1* 1*  1* 1*  
  Yes                                             0.69 (0.58, 0.82) <0.001 0.56 (0.47, 0.67) <0.001 
Coronary heart disease 
  No 1* 1*  1* 1*  
 Yes 1.07 (0.92, 1.24) 0.402 0.97 (0.83, 1.14) 0.706 
Congestive-cardiac failure                  
  No                                      1* 1*  1* 1*  
 Yes                               0.88 (0.72, 1.07) 0.208 0.76 (0.62, 0.93) 0.008 
Diabetes 
No 1* 1*  1* 1*  
Yes 0.75 (0.63, 0.89) 0.001 0.65 (0.54, 0.77) <0.001 
Chronic Obstructive Pulmonary Disease 
   No 1* 1*  1* 1*  
  Yes                                             0.79 (0.65, 0.96) 0.021 0.51 (0.41, 0.63) <0.001 
Bowel Incontinence 
   No 1* 1*  1* 1*  
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    Yes                                     1.11 (0.91, 1.35) 0.300 1.08 (0.88, 1.33) 0.422 
Urinary Incontinence ¶ 
   No 1* 1*  1* 1*  
   Yes 1.07 (0.938, 1.24) 0.287 1.13 (0.97, 1.30) 0.110 
Urinary tract infection 
    No 1* 1*  1* 1*  
   Yes                                          0.93 (0.69, 1.26) 0.654 1.19 (0.88, 1.62) 0.248 
Falls 
  No 1* 1*  1* 1*  
  Yes 1.04 (0.91, 1.18) 0.581 1.07 (0.93, 1.24) 0.286 
Fracture †† 
   No 1* 1*  1* 1*  
   Yes                                          1.08 (0.77, 1.51) 0.641 0.96 (0.67, 1.36) 0.838 
*= Reference value, †= 1 missing, ‡= not spouse / partner, §=2 missing, ||= in last 90 days, ¶=16 
missing, †† =4 missing. 
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